Risk grouping and early prevention for non-compaction cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at people with a rare heart muscle condition called non-compaction cardiomyopathy. The goal is to better understand risks and find ways to prevent problems early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your family member must have been diagnosed with non-compaction of the heart muscle (a condition where the heart muscle has a spongy texture).
- The diagnosis must be confirmed by tests like an echo (ultrasound), ECG (heart tracing), MRI, biopsy, or genetic testing.
- You must be willing to join the study and sign a consent form.
- You must have complete medical records available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to better understand and treat cardiomyopathy by studying patients' hearts with advanced tests. It seeks to find new ways to prevent or manage the condition early.
This trial evaluates early prevention and treatment strategies for arrhythmogenic cardiomyopathy (ACM), a heart condition that can cause abnormal heart rhythms. It aims to improve care by using advanced tests like heart imaging and genetic sequencing to guide treatment.
This study looks at people with left ventricular non-compaction (a condition where the heart muscle is spongy) to find what factors might predict their health risks. By joining, you'll help doctors better understand and care for others with this condition.
This study looks at different types of heart muscle diseases that are not caused by blocked arteries (non-ischemic cardiomyopathies). It aims to better understand how to diagnose, predict outcomes, and treat these conditions by gathering information from many patients over time.
This registry study collects information, blood samples, and MRI images from people with non-ischemic cardiomyopathy (a heart muscle disease not caused by blocked arteries). By joining, you help researchers better understand the condition and find new ways to diagnose and treat it.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Hear when a new Isolated Noncompaction of the Ventricular Myocardium trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.